296 results about "Chronic disorders" patented technology

This invention encompasses methods for the treatment and prevention of disorders that include, but are not limited to, eating disorders; weight gain; obesity; irritable bowel syndrome; obsessive-compulsive disorders; platelet adhesion; apnea; affective disorders such as attention deficit disorders, depression, and anxiety; male and female sexual function disorders; restless leg syndrome; osteoarthritis; substance abuse including nicotine and cocaine addiction; narcolepsy; pain such as neuropathic pain, diabetic neuropathy, and chronic pain; migraines; cerebral function disorders; chronic disorders such as premenstrual syndrome; and incontinence. The invention further encompasses pharmaceutical compositions and dosage forms which comprise optically pure (+) sibutramine, optionally in combination with a phosphodiesterase inhibitor or a lipase inhibitor.

A method of treating chronic disorders associated with the presence of abnormal microflora or an abnormal distribution of microflora in the gastrointestinal tract involves removing the host's existing enteric microflora and substitution of feces from a disease screener donor or composition comprising microorganism selected from the group consisting of Bacteroides and E. coli.

The invention discloses a composite enzyme beverage and a preparation process method thereof. The composite enzyme beverage is prepared from five cereals, fruits and vegetables, edible plants and edible fungi as main raw materials through common fermentation; three-step fermentation is realized by using microzyme, acetic acid bacteria and lactic acid bacteria; and substep fermentation for different strains is adopted at different stages in the manufacturing process, so that the demands of a human body on the efficacies of health and nutrition are met. According to the composite enzyme beverage disclosed by the invention, the mixture ratio of the raw materials is more gentle, more pure natural organic raw materials are used and the three-step fermentation is realized by the microzyme, the acetic acid bacteria and the lactic acid bacteria; and the composite enzyme beverage retains original vitamins and carbohydrate of the fruits and vegetables, is rich in various B-group vitamins and various amino acids, is a nutrient necessary for eliminating the human fatigue and particularly benefits people suffered from chronic disease syndrome. Particularly after coarse grains are fermented, insoluble dietary fibers can be dissolved into small molecular substances which are easily digested and absorbed by the human body, and thus the digestion and intake of nutritive substances by the human body can be enhanced.

This invention concerns new methods and compositions that are useful in preventing and ameliorating cachexia, the clinical syndrome of poor nutritional status and bodily wasting associated with cancer and other chronic diseases. More particularly, the invention relates to aromatic guanylhydrazone (more properly termed amidinohydrazone) compositions and their use to inhibit the uptake of arginine by macrophages and/or its conversion to urea. These compositions and methods are also useful in preventing the generation of nitric oxide (NO) by cells, and so to prevent NO-mediated inflammation and other responses in persons in need of same. In another embodiment, the compounds can be used to inhibit arginine uptake in arginine-dependent tumors and infections.

The present invention relates to the field of supporting arrangements, devices or systems for the rehabilitation and treatment of patients or animals suffering from motor disabilities resulting from surgery, chronic disorders, accidents and the like. More specifically, the present invention refers to aerial or overhead supporting arrangements, devices or systems that allow the patient or animal under treatment to remain suspended.

The present invention relates to binding moieties that specifically bind to a conformational epitope of C5a, in particular human C5a. Preferred binding moieties are anti-C5a antibodies that bind to this conformational epitope. The binding moieties described herein are useful as active agents in pharmaceutical compositions for the treatment and prevention of various acute and chronic diseases, in particular acute inflammatory diseases, such as the systemic inflammatory response syndrome (SIRS), and different degrees of sepsis including sepsis, severe sepsis, and septic shock.

Systems and methods assist with managing a chronic disease of a user such as a chronic respiratory or cardiac disease. The system may include a physiological monitor adapted to be carried by the user and operative to sense a physiological parameter of the user. The system may include a management device operatively coupled with the physiological monitor to receive the sensed physiological parameter of the user. The management device, such as with an included processor, may be configured to analyze the physiological and/or environmental parameters to detect a trigger pattern of the parameters, the trigger pattern indicative of a probable event of exacerbation of the chronic respiratory and/or cardiac condition. The management device may then generate automated responses based on the trigger pattern such as by providing instructions for activities and/or treatment for the chronic condition.

Disclosed herein are compositions and methods for treating ocular diseases, inter alia, diabetic macular edema, age-related macular degeneration (wet form), choroidal neovascularization, diabetic retinopathy, retinal vein occlusion (central or branch), ocular trauma, surgery induced edema, surgery induced neovascularization, cystoid macular edema, ocular ischemia, uveitis, and the like. These diseases or conditions are characterized by changes in the ocular vasculature whether progressive or non-progressive, whether a result of an acute disease or condition, or a chronic disease or condition.

The invention discloses a chronic disease condition change event prediction device based on a recurrent neural network, and the device comprises a memory, a processor, and a computer program, a preprocessing module and a chronic disease condition change event prediction model are stored in the memory, and the prediction model comprises a preprocessing module, a condition feature extraction module,and a classification module. When the processor executes a computer program, the following steps are realized: receiving long-term longitudinal data generated by multiple hospitalization of a patient, performing data preprocessing on the number by the preprocessing module, and reconstructing the data of each hospitalization into a feature vector as a to-be-tested data set; Taking the to-be-detected data set as input, extracting disease characteristics by a disease characteristic extraction module, and inputting the disease characteristics into a classification module; And enabling the classification module to output the prediction probability of various events indicating that the illness state changes. The prediction device can predict the event that the chronic disease patient has markeddisease condition change in the target time window, thereby assisting the doctor to formulate reasonable diagnosis and treatment measures and reducing the medical expenditure.

Disclosed are pharmaceutical compositions and topical formulations thereof that include multiple, phytochemically-active, nutraceutical compounds, and that possess potent anti-inflammatory and extracellular matrix-stabilizing properties both in vitro and in vivo. Also disclosed are prophylactic and therapeutic methods, as well as dosing regimens and medicaments for use in preventing chronic disease, for treating acute or long-term inflammatory-mediated conditions in affected or at-risk subjects, and for stabilizing one or more components of the mammalian extracellular matrix.

The invention discloses a fruit and vegetable enzyme solid beverage. The fruit and vegetable enzyme solid beverage comprises the following components in parts by weight: 0.8-1.2 parts of excellent bacteria 80 enzyme, 2-4 parts of smooth enzyme, 1.8-2.4 parts of comprehensive grain-bean enzyme, 2.8-3.2 parts of high fiber vegetable and fruit enzyme, 0.8-1.2 parts of soybean compound enzyme, 0.8-2.4 parts of fruit enzyme beverage and 0.4-0.6 part of an emulsifier. The invention also discloses a method for preparing the fruit and vegetable enzyme solid beverage. The fruit and vegetable enzyme solid beverage is prepared by the steps of molecule fusion, homogeneous emulsification and spray drying. The fruit and vegetable enzyme solid beverage provided by the invention is full in nutrition and multiple in enzyme types; patients with chronic diseases such as the high blood pressure, diabetes and obesity can recover health rapidly.

Dysfunctional or exhausted T cells arise in chronic diseases including chronic viral infections and cancer, and express high levels of co-inhibitory receptors. Therapeutic blockade of these receptors has clinical efficacy in the treatment of cancer. While co-inhibitory receptors are co-expressed, the triggers that induce them and the transcriptional regulators that drive their co-expression have not been identified. The immunoregulatory cytokine IL-27 induces a gene module in T cells that includes several known co-inhibitory receptors (Tim-3, Lag-3, and TIGIT). The present invention provides a novel immunoregulatory network as well as novel cell surface molecules that have an inhibitory function in the tumor microenvironment. The present invention further provides the novel discovery that the transcription factors Prdm1 and c-Maf cooperatively regulate the expression of the co-inhibitory receptor module. This critical molecular circuit underlies the co-expression of co-inhibitory receptors in dysfunctional T cells and identifies novel regulators of T cell dysfunction.

The described easy access apparel provides ever day wear that is effective to reduce the stigma of a chronic illness, improve the experience of receiving treatment for a chronic illness, and facilitates access to and utilization of a percutaneous access site.